13/120
0.5 / 5 stars
All 120 Win/Lose results shown below
REPL Roast Me summary
Replimune Group, Inc. (REPL). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
Trailing 1 year (4 quarters): 2 wins, 10 lossesLast fetched: 24 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinREPL / S&P 44.71% / 15.20% |
LoseREPL / S&P REPL unavailable / 15.00% |
LoseREPL / S&P REPL unavailable / 50.40% |
| 2026-Q10/3 |
LoseREPL / S&P -21.30% / -4.33% |
LoseREPL / S&P REPL unavailable / 11.30% |
LoseREPL / S&P REPL unavailable / 27.70% |
| 2025-Q41/3 |
WinREPL / S&P 131.98% / 2.65% |
LoseREPL / S&P REPL unavailable / 9.00% |
LoseREPL / S&P REPL unavailable / 13.40% |
| 2025-Q30/3 |
LoseREPL / S&P -54.90% / 8.12% |
LoseREPL / S&P REPL unavailable / 4.61% |
LoseREPL / S&P REPL unavailable / 13.45% |
| 2025-Q20/3 |
LoseREPL / S&P -4.72% / 10.94% |
LoseREPL / S&P REPL unavailable / 4.83% |
LoseREPL / S&P REPL unavailable / 10.63% |
| 2025-Q10/3 |
LoseREPL / S&P -19.49% / -4.27% |
LoseREPL / S&P REPL unavailable / 4.98% |
LoseREPL / S&P REPL unavailable / 10.57% |
| 2024-Q41/3 |
WinREPL / S&P 10.49% / 2.41% |
LoseREPL / S&P REPL unavailable / 5.25% |
LoseREPL / S&P REPL unavailable / 6.15% |
| 2024-Q31/3 |
WinREPL / S&P 21.78% / 5.89% |
LoseREPL / S&P REPL unavailable / 5.89% |
LoseREPL / S&P REPL unavailable / 6.11% |
| 2024-Q21/3 |
WinREPL / S&P 10.16% / 4.28% |
LoseREPL / S&P REPL unavailable / 5.38% |
LoseREPL / S&P REPL unavailable / 5.12% |
| 2024-Q10/3 |
LoseREPL / S&P -3.08% / 10.56% |
LoseREPL / S&P REPL unavailable / 5.71% |
LoseREPL / S&P REPL unavailable / 5.59% |
| 2023-Q40/3 |
LoseREPL / S&P -50.73% / 11.69% |
LoseREPL / S&P REPL unavailable / 6.81% |
LoseREPL / S&P REPL unavailable / 7.78% |
| 2023-Q30/3 |
LoseREPL / S&P -26.31% / -3.27% |
LoseREPL / S&P REPL unavailable / 7.52% |
LoseREPL / S&P REPL unavailable / -5.03% |
| 2023-Q21/3 |
WinREPL / S&P 31.48% / 8.74% |
LoseREPL / S&P REPL unavailable / 9.50% |
LoseREPL / S&P REPL unavailable / -8.57% |
| 2023-Q10/3 |
LoseREPL / S&P -35.07% / 7.50% |
LoseREPL / S&P REPL unavailable / 10.77% |
LoseREPL / S&P REPL unavailable / -15.69% |
| 2022-Q41/3 |
WinREPL / S&P 57.50% / 7.56% |
LoseREPL / S&P REPL unavailable / 11.88% |
LoseREPL / S&P REPL unavailable / -17.99% |
| 2022-Q31/3 |
WinREPL / S&P -1.20% / -4.88% |
LoseREPL / S&P REPL unavailable / 13.47% |
LoseREPL / S&P REPL unavailable / -1.41% |
| 2022-Q21/3 |
WinREPL / S&P 2.94% / -16.10% |
LoseREPL / S&P REPL unavailable / 13.71% |
LoseREPL / S&P REPL unavailable / 11.04% |
| 2022-Q10/3 |
LoseREPL / S&P -37.34% / -4.60% |
LoseREPL / S&P REPL unavailable / 15.97% |
LoseREPL / S&P REPL unavailable / 42.23% |
| 2021-Q40/3 |
LoseREPL / S&P -8.57% / 11.03% |
LoseREPL / S&P REPL unavailable / 15.00% |
LoseREPL / S&P REPL unavailable / 96.40% |
| 2021-Q30/3 |
LoseREPL / S&P -22.85% / 0.58% |
LoseREPL / S&P REPL unavailable / 10.77% |
LoseREPL / S&P REPL unavailable / 69.42% |
| 2021-Q21/3 |
WinREPL / S&P 25.93% / 8.55% |
LoseREPL / S&P REPL unavailable / 6.58% |
LoseREPL / S&P REPL unavailable / 51.81% |
| 2021-Q10/3 |
LoseREPL / S&P -20.03% / 6.17% |
LoseREPL / S&P REPL unavailable / -1.06% |
LoseREPL / S&P REPL unavailable / 7.39% |
| 2020-Q41/3 |
WinREPL / S&P 65.73% / 12.15% |
LoseREPL / S&P REPL unavailable / -3.72% |
LoseREPL / S&P REPL unavailable / -33.42% |
| 2020-Q30/3 |
LoseREPL / S&P -7.36% / 8.93% |
LoseREPL / S&P REPL unavailable / -2.04% |
LoseREPL / S&P REPL unavailable / -27.10% |
| 2020-Q21/3 |
WinREPL / S&P 149.25% / 20.54% |
LoseREPL / S&P REPL unavailable / -0.46% |
LoseREPL / S&P REPL unavailable / -27.11% |
| 2020-Q10/3 |
LoseREPL / S&P -30.52% / -19.60% |
LoseREPL / S&P REPL unavailable / 3.47% |
LoseREPL / S&P REPL unavailable / -14.75% |
| 2019-Q40/3 |
LoseREPL / S&P 3.24% / 9.07% |
LoseREPL / S&P REPL unavailable / 5.36% |
LoseREPL / S&P REPL unavailable / 2.99% |
| 2019-Q30/3 |
LoseREPL / S&P -5.18% / 1.70% |
LoseREPL / S&P REPL unavailable / 5.02% |
LoseREPL / S&P REPL unavailable / 0.21% |
| 2019-Q20/3 |
LoseREPL / S&P -3.68% / 4.30% |
LoseREPL / S&P REPL unavailable / 6.64% |
LoseREPL / S&P REPL unavailable / 8.65% |
| 2019-Q11/3 |
WinREPL / S&P 52.20% / 13.65% |
LoseREPL / S&P REPL unavailable / 8.12% |
LoseREPL / S&P REPL unavailable / 14.29% |
| 2018-Q40/3 |
LoseREPL / S&P -37.89% / -13.52% |
LoseREPL / S&P REPL unavailable / 9.05% |
LoseREPL / S&P REPL unavailable / 18.23% |
| 2018-Q30/3 |
LoseREPL / S&P REPL unavailable / 7.71% |
LoseREPL / S&P REPL unavailable / 10.21% |
LoseREPL / S&P REPL unavailable / 19.06% |
| 2018-Q20/3 |
LoseREPL / S&P REPL unavailable / 3.43% |
LoseREPL / S&P REPL unavailable / 9.03% |
LoseREPL / S&P REPL unavailable / 14.46% |
| 2018-Q10/3 |
LoseREPL / S&P REPL unavailable / -0.76% |
LoseREPL / S&P REPL unavailable / 7.68% |
LoseREPL / S&P REPL unavailable / 12.46% |
| 2017-Q40/3 |
LoseREPL / S&P REPL unavailable / 6.64% |
LoseREPL / S&P REPL unavailable / 7.03% |
LoseREPL / S&P REPL unavailable / 13.82% |
| 2017-Q30/3 |
LoseREPL / S&P REPL unavailable / 4.48% |
LoseREPL / S&P REPL unavailable / 5.68% |
LoseREPL / S&P REPL unavailable / 17.57% |
| 2017-Q20/3 |
LoseREPL / S&P REPL unavailable / 3.09% |
LoseREPL / S&P REPL unavailable / 4.83% |
LoseREPL / S&P REPL unavailable / 17.74% |
| 2017-Q10/3 |
LoseREPL / S&P REPL unavailable / 6.07% |
LoseREPL / S&P REPL unavailable / 3.67% |
LoseREPL / S&P REPL unavailable / 13.32% |
| 2016-Q40/3 |
LoseREPL / S&P REPL unavailable / 3.82% |
LoseREPL / S&P REPL unavailable / 2.09% |
LoseREPL / S&P REPL unavailable / 7.05% |
| 2016-Q30/3 |
LoseREPL / S&P REPL unavailable / 3.85% |
LoseREPL / S&P REPL unavailable / 0.20% |
LoseREPL / S&P REPL unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | REPL total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 186.95% | 20.78% |
| Annualized return | 186.95% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | REPL total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -53.44% | 83.14% |
| Annualized return | -14.18% | 12.86% |
10Y · 2018-07-20 to 2026-08-28
| Metric | REPL total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 2.21% | 319.30% |
| Annualized return | 0.22% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-24.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |